Cancer BiologybioRxiv
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
J. M. Pita, E. Raspe, K. Coulonval…·P. P. Roger
This study shows that CDK4 phosphorylation status predicts response to CDK4/6 inhibitors in thyroid carcinomas and supports combining them with BRAF/MEK inhibitors to prevent resistance.
DOI 10.3389/fendo.2023.1247542